Matches in SemOpenAlex for { <https://semopenalex.org/work/W2615691774> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2615691774 endingPage "36" @default.
- W2615691774 startingPage "29" @default.
- W2615691774 abstract "Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. Patients with advanced solid malignancies and hepatic impairment were enrolled into one of four cohorts: normal [bilirubin (bili) < upper limit of normal (ULN)], mild (ULN < bili ≤ 1.5 × ULN), moderate (1.5 × ULN < bili ≤ 3×ULN), and severe (3 × ULN < bili < 10 × ULN) dysfunction. Patients received oral vismodegib 150 mg daily. Plasma PK samples on days 1, 3, 5, and 8 were collected. Vismodegib therapy was continued until disease progression, intolerable toxicity, or withdrawal of consent. Thirty-one patients were accrued: nine normal, eight mild, eight moderate, and six severe. Four patients experienced dose-limiting toxicity of hyperbilirubinemia on study: one in the moderate cohort and three in the severe cohort. Six patients died within 30 days after the last dose of vismodegib. All deaths were attributed to disease progression. Observed maximal and average steady-state concentrations and AUC of vismodegib at steady state (day 8) were similar across cohorts. Average AAG concentrations in patients with hepatic impairment were comparable to those of patients with normal hepatic function. Hepatic impairment does not appear to impact vismodegib PK, and therefore, dose adjustment is not necessary in this special population. The study was influenced by the high number of patients with hepatocellular carcinoma with advanced cirrhosis; rendering it difficult to draw any causal relationships between vismodegib exposure and the serious adverse events." @default.
- W2615691774 created "2017-05-26" @default.
- W2615691774 creator A5007469278 @default.
- W2615691774 creator A5017092656 @default.
- W2615691774 creator A5023535490 @default.
- W2615691774 creator A5033626596 @default.
- W2615691774 creator A5036578095 @default.
- W2615691774 creator A5038475478 @default.
- W2615691774 creator A5064953304 @default.
- W2615691774 creator A5078202936 @default.
- W2615691774 creator A5080500055 @default.
- W2615691774 creator A5081273660 @default.
- W2615691774 date "2017-05-18" @default.
- W2615691774 modified "2023-10-17" @default.
- W2615691774 title "Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment" @default.
- W2615691774 cites W2003055758 @default.
- W2615691774 cites W2019607817 @default.
- W2615691774 cites W2030199762 @default.
- W2615691774 cites W2059456940 @default.
- W2615691774 cites W2096155765 @default.
- W2615691774 cites W2101616608 @default.
- W2615691774 cites W2105152393 @default.
- W2615691774 cites W2108707301 @default.
- W2615691774 cites W2125849751 @default.
- W2615691774 cites W2139499843 @default.
- W2615691774 cites W2139975233 @default.
- W2615691774 cites W2155854765 @default.
- W2615691774 cites W2345852033 @default.
- W2615691774 cites W2408800771 @default.
- W2615691774 doi "https://doi.org/10.1007/s00280-017-3315-8" @default.
- W2615691774 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5520972" @default.
- W2615691774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28523596" @default.
- W2615691774 hasPublicationYear "2017" @default.
- W2615691774 type Work @default.
- W2615691774 sameAs 2615691774 @default.
- W2615691774 citedByCount "21" @default.
- W2615691774 countsByYear W26156917742018 @default.
- W2615691774 countsByYear W26156917742019 @default.
- W2615691774 countsByYear W26156917742020 @default.
- W2615691774 countsByYear W26156917742021 @default.
- W2615691774 countsByYear W26156917742022 @default.
- W2615691774 crossrefType "journal-article" @default.
- W2615691774 hasAuthorship W2615691774A5007469278 @default.
- W2615691774 hasAuthorship W2615691774A5017092656 @default.
- W2615691774 hasAuthorship W2615691774A5023535490 @default.
- W2615691774 hasAuthorship W2615691774A5033626596 @default.
- W2615691774 hasAuthorship W2615691774A5036578095 @default.
- W2615691774 hasAuthorship W2615691774A5038475478 @default.
- W2615691774 hasAuthorship W2615691774A5064953304 @default.
- W2615691774 hasAuthorship W2615691774A5078202936 @default.
- W2615691774 hasAuthorship W2615691774A5080500055 @default.
- W2615691774 hasAuthorship W2615691774A5081273660 @default.
- W2615691774 hasBestOaLocation W26156917742 @default.
- W2615691774 hasConcept C126322002 @default.
- W2615691774 hasConcept C126894567 @default.
- W2615691774 hasConcept C143998085 @default.
- W2615691774 hasConcept C197934379 @default.
- W2615691774 hasConcept C2778804307 @default.
- W2615691774 hasConcept C2779545874 @default.
- W2615691774 hasConcept C3019992690 @default.
- W2615691774 hasConcept C71924100 @default.
- W2615691774 hasConcept C72563966 @default.
- W2615691774 hasConcept C90924648 @default.
- W2615691774 hasConceptScore W2615691774C126322002 @default.
- W2615691774 hasConceptScore W2615691774C126894567 @default.
- W2615691774 hasConceptScore W2615691774C143998085 @default.
- W2615691774 hasConceptScore W2615691774C197934379 @default.
- W2615691774 hasConceptScore W2615691774C2778804307 @default.
- W2615691774 hasConceptScore W2615691774C2779545874 @default.
- W2615691774 hasConceptScore W2615691774C3019992690 @default.
- W2615691774 hasConceptScore W2615691774C71924100 @default.
- W2615691774 hasConceptScore W2615691774C72563966 @default.
- W2615691774 hasConceptScore W2615691774C90924648 @default.
- W2615691774 hasFunder F4320307779 @default.
- W2615691774 hasIssue "1" @default.
- W2615691774 hasLocation W26156917741 @default.
- W2615691774 hasLocation W26156917742 @default.
- W2615691774 hasLocation W26156917743 @default.
- W2615691774 hasLocation W26156917744 @default.
- W2615691774 hasOpenAccess W2615691774 @default.
- W2615691774 hasPrimaryLocation W26156917741 @default.
- W2615691774 hasRelatedWork W1803222855 @default.
- W2615691774 hasRelatedWork W2071250613 @default.
- W2615691774 hasRelatedWork W2153743952 @default.
- W2615691774 hasRelatedWork W2607360241 @default.
- W2615691774 hasRelatedWork W2901949882 @default.
- W2615691774 hasRelatedWork W3045377858 @default.
- W2615691774 hasRelatedWork W3126292731 @default.
- W2615691774 hasRelatedWork W3196037314 @default.
- W2615691774 hasRelatedWork W4304804698 @default.
- W2615691774 hasRelatedWork W1920413731 @default.
- W2615691774 hasVolume "80" @default.
- W2615691774 isParatext "false" @default.
- W2615691774 isRetracted "false" @default.
- W2615691774 magId "2615691774" @default.
- W2615691774 workType "article" @default.